New Treatment Paradigm in Chronic CAD and/or PAD; Which Patient Benefit the Most from Rivaroxaban 2.5mg + ASA?
[Speaker] 배장환/충북의대
Considering Renal Outcome for NVAF Patient; Insights from Rivaroxaban's Clinical Trials
[Speaker] 박형섭/계명의대